Short-term treatment with GLP-1 increases pulsatile insulin secretion in Type II diabetes with no effect on orderliness

Diabetologia

Volumn 43, Issue 5, 2000, Pages 583-588

  Juhl, C B ^a   Schmitz, O ^a   Pincus, S ^c   Holst, J J ^c   Veldhuis, J ^b   Porksen N ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF VIRGINIA   (United States)

^c Aarhus Kommunehospital ^*

Author keywords

GLP 1; Human; Insulin; Insulin secretion; Pulsatility; Time series; Type II diabetes

Indexed keywords

GLUCAGON LIKE PEPTIDE 1 [7-36] AMIDE; INSULIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIABETES MELLITUS; HUMAN; INSULIN RELEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; PULSATILE HORMONE RELEASE; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

BLOOD GLUCOSE; C-PEPTIDE; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 2; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; HUMANS; INSULIN; MIDDLE AGED; PEPTIDE FRAGMENTS; PERIODICITY; PROTEIN PRECURSORS;

EID: 0034077302     PISSN: 0012186X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001250051347     Document Type: Article

References (27)

1. 1. Polonsky KS, Given BD, Hirsch LJ et al. (1988) Abnormal patterns of insulin secretion in non-insulin-dependent diabetes mellitus. N Engl J Med 318:1231-1239
2. 2. Lang DA, Matthews DR, Burnett M, Turner RC (1981) Brief, irregular oscillations of basal plasma insulin and glucose concentrations in diabetic man. Diabetes 30: 435-439
3. 3. Matthews DR, Naylor BA, Jones RG, Ward GM, Turner RC (1983) Pulsatile insulin has greater hypoglycemic effect than continuous delivery. Diabetes 32: 617-621
4. 4. Komjati M, Bratusch-Marrain P, Waldhausl W (1986) Superior efficacy of pulsatile versus continuous hormone exposure on hepatic glucose production in vitro. Endocrinology 118: 312-319
5. 5. Bratusch-Marrain PR, Komjati M, Waldhausl WK (1986) Efficacy of pulsatile versus continuous insulin administration on hepatic glucose production and glucose utilization in type I diabetic humans. Diabetes 35: 922-926
6. 6. Porksen N, Hussain MA, Bianda TL et al. (1997) IGF-I inhibits burst mass of pulsatile insulin secretion at supraphysiological and low IGF-I infusion rates. Am J Physiol 272: E352-E358
7. 7. Porksen N, Munn SR, Steers JL, Veldhuis JD, Butler PC (1996) Effects of somatostatin on pulsatile insulin secretion: elective inhibition of insulin burst mass. Am J Physiol 270: E1043-E1049
8. 8. Matthews DR, Lang DA, Burnett MA, Turner RC (1983) Control of pulsatile insulin secretion in man. Diabetologia 24: 231-237
9. 9. Porksen NK, Grøfte T, Nyholm B et al. (1998) Glucagon-like peptide 1 increases mass but not frequency or orderliness of pulsatile insulin secretion. Diabetes 47: 45-49
10. 10. Juhl CB, Porksen NK, Sturis J et al. (1999) Repaglinide amplifies insulin secretory burst mass without affecting burst frequency. Diabetes [Suppl] A245 (Abstract)
11. 11. Orskov C (1992) Glucagon-like peptide-1, a new hormone of the entero-insular axis. Diabetologia 35: 701-711
12. 12. Komatsu R, Matsuyama T, Namba M et al. (1989) Glucagonostatic and insulinotropic action of glucagonlike peptide I-(7-36)-amide. Diabetes 38: 902-905
13. 13. Porksen N, Munn S, Ferguson D, O'Brien T, Veldhuis J, Butler P (1994) Coordinate pulsatile insulin secretion by chronic intraportally transplanted islets in the isolated perfused rat liver. J Clin Invest 94: 219-227
14. 2+ in mouse pancreatic beta-cells. Diabetes 47: 1266-1273
15. 15. Meneilly GS, Veldhuis JD, Elahi D (1999) Disruption of the pulsatile and entropic modes of insulin release during an unvarying glucose stimulus in elderly individuals. J Clin Endocrinol Metab 84: 1938-1943
16. 16. Balks HJ, Holst JJ, von-zur-Muhlen A, Brabant G (1997) Rapid oscillations in plasma glucagon-like peptide-1 (GLP-1) in humans: cholinergic control of GLP-1 secretion via muscarinic receptors. J Clin Endocrinol Metab 82: 786-790
17. 17. Rachman J, Gribble FM, Barrow BA, Levy JC, Buchanan KD, Turner RC (1996) Normalization of insulin responses to glucose by overnight infusion of glucagon-like peptide 1 (7-36) amide in patients with NIDDM. Diabetes 45: 1524-1530
18. 18. Byrne MM, Gliem K, Wank U et al. (1998) Glucagon-like peptide 1 improves the ability of the beta-cell to sense and respond to glucose in subjects with impaired glucose tolerance. Diabetes 47: 1259-1265
19. 19. Andersen L, Dinesen B, Jorgensen PN, Poulsen F, Roder ME (1993) Enzyme immunoassay for intact human insulin in serum or plasma. Clin Chem 39: 578-582
20. 20. Veldhuis JD, Carlson ML, Johnson ML (1987) The pituitary gland secretes in bursts: appraising the nature of glandular secretory impulses by simultaneous multiple-parameter deconvolution of plasma hormone concentrations. Proc Natl Acad Sci USA 84: 7686-7690
21. 21. Porksen NK, Nyholm B, Veldhuis JD, Butler PC, Schmitz O (1997) In humans at least 75% of insulin secretion arises from punctuated secretory bursts. Am J Physiol 273: E908-E914
22. 22. Pincus SM (1991) Approximate Entropy as a measure of system complexity. Proc Natl Acad Sci USA 88: 2297-2301
23. 23. Jenkins GM, Watts DG (1966) Spectral analysis and its applications. Holden-Day, San Francisco
24. 24. Chatfield C (1996) The analysis of time series. An introduction. Chapman and Hall, London
25. 25. Ritzel R, Schulte M, Nauck M et al. (1998) GLP-1 increases secretory burst mass of pulsatile insulin secretion in patients with impaired glucose tolerance and Type II diabetes. Diabetologia [Suppl 1] A182 (Abstract)
26. 26. Orskov C, Wettergren A, Holst JJ (1996) Secretion of the incretin hormones glucagon-like peptide-1 and gastric inhibitory polypeptide correlates with insulin secretion in normal man throughout the day. Scand J Gastroenterol 31: 665-670
27. 27. Gromada J, Bokvist K, Ding WG, Holst JJ, Nielsen JH, Rorsman P (1998) Glucagon-like peptide 1 (7-36) amide stimulates exocytosis in human pancreatic beta-cells by both proximal and distal regulatory steps in stimulus-secretion coupling. Diabetes 47: 57-65